ClinConnect ClinConnect Logo
Search / Trial NCT00356395

Safety and Effects of Ramipril Combined With Candesartan

Launched by GACHON UNIVERSITY GIL MEDICAL CENTER · Jul 25, 2006

Trial Information

Current as of June 23, 2025

Completed

Keywords

Endothelial Function, Insulin Resistance, Adipocytokines

ClinConnect Summary

Forty patients will be given ramipril 10 mg and placebo, ramipril 10 mg and candesartan 16 mg, or candesartan 16 mg and placebo daily in a randomized, double-blind, placebo-controlled cross-over trial with three treatment arms and two washout periods (each 2 months).

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • patients with mild to moderate hypertension
  • Exclusion Criteria:
  • We will exclude patients with severe hypertension, unstable angina, acute myocardial infarction, or renal insufficiency.

About Gachon University Gil Medical Center

Gachon University Gil Medical Center is a leading healthcare institution located in South Korea, renowned for its commitment to advancing medical research and clinical excellence. As a prominent clinical trial sponsor, the center leverages its comprehensive expertise in various medical fields to facilitate innovative research initiatives aimed at improving patient outcomes. With a strong focus on collaboration, Gachon University Gil Medical Center engages in partnerships with academic institutions, industry leaders, and healthcare professionals to drive the development of groundbreaking therapies and treatment modalities. Its state-of-the-art facilities and dedicated research teams ensure rigorous adherence to ethical standards and regulatory compliance, positioning the center at the forefront of clinical research in the region.

Locations

Patients applied

0 patients applied

Trial Officials

Kwang K Koh, MD

Principal Investigator

Cardiology, Gil Heart Center, Gachon Medical School

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials